| Var Name      | Description   |
| ------------- |:------------- |
|ptnt_pct_use_her_neoadjuvant| Percent of neoadjuvant patients using HERCEPTIN|
|ptnt_pct_use_her_adjuvant| Percent of adjuvant patients using HERCEPTIN|
|ptnt_pct_use_her_1L| Percent of 1st line patients using HERCEPTIN|
|ptnt_pct_use_her_2Lplus| Percent of 2nd or above line patients using HERCEPTIN|
|avg_her_inf_neoadjuvant| Average HERCEPTIN infusion count for neoadjuvant patients|
|avg_her_inf_adjuvant| Average HERCEPTIN infusion count for adjuvant patients|
|avg_her_inf_1L| Average HERCEPTIN infusion count for 1st line patients|
|avg_her_inf_2Lplus| Average HERCEPTIN infusion count for 2nd and above line patients|
|avg_her_cmplnt_drtn_neoadjuvant| Average HERCEPTIN compliance duration for neoadjuvant patients|
|avg_her_cmplnt_drtn_adjuvant| Average HERCEPTIN compliance duration for adjuvant patients|
|avg_her_cmplnt_drtn_1L| Average HERCEPTIN compliance duration for 1st line patients|
|avg_her_cmplnt_drtn_2Lplus| Average HERCEPTIN compliance duration for 2nd and above line patients|
|ptnt_pct_use_per_neoadjuvant| Percent of neoadjuvant patients using PERJETA|
|ptnt_pct_use_per_adjuvant| Percent of adjuvant patients using PERJETA|
|ptnt_pct_use_per_1L| Percent of 1st line patients using PERJETA||
|ptnt_pct_use_per_2Lplus| Percent of 2nd or above line patients using PERJETA|
|avg_per_inf_neoadjuvant| Average PERJETA infusion count for neoadjuvant patients|
|avg_per_inf_adjuvant| Average PERJETA infusion count for adjuvant patients|
|avg_per_inf_1L| Average PERJETA infusion count for 1st line patients|
|avg_per_inf_2Lplus| Average PERJETA infusion count for 2nd and above line patients|
|avg_per_cmplnt_drtn_neoadjuvant| Average PERJETA compliance duration for neoadjuvant patients|
|avg_per_cmplnt_drtn_adjuvant| Average PERJETA compliance duration for adjuvant patients|
|avg_per_cmplnt_drtn_1L| Average PERJETA compliance duration for 1st line patients|
|avg_per_cmplnt_drtn_2Lplus| Average PERJETA compliance duration for 2nd and above line patients|
|ptnt_pct_use_kad_neoadjuvant| Percent of neoadjuvant patients using KADCYLA|
|ptnt_pct_use_kad_adjuvant| Percent of adjuvant patients using KADCYLA|
|ptnt_pct_use_kad_1L| Percent of 1st line patients using KADCYLA||
|ptnt_pct_use_kad_2Lplus| Percent of 2nd or above line patients using KADCYLA|
|avg_kad_inf_neoadjuvant| Average KADCYLA infusion count for neoadjuvant patients|
|avg_kad_inf_adjuvant| Average KADCYLA infusion count for adjuvant patients|
|avg_kad_inf_1L| Average KADCYLA infusion count for 1st line patients|
|avg_kad_inf_2Lplus| Average KADCYLA infusion count for 2nd and above line patients|
|avg_kad_cmplnt_drtn_neoadjuvant| Average KADCYLA compliance duration for neoadjuvant patients|
|avg_kad_cmplnt_drtn_adjuvant| Average KADCYLA compliance duration for adjuvant patients|
|avg_kad_cmplnt_drtn_1L| Average KADCYLA compliance duration for 1st line patients|
|avg_kad_cmplnt_drtn_2Lplus| Average KADCYLA compliance duration for 2nd and above line patients|
|avg_tax_inf_neoadjuvant| Average TAXANE infusion count for neoadjuvant patients|
|avg_tax_inf_adjuvant| Average TAXANE infusion count for adjuvant patients|
|avg_tax_inf_1L| Average TAXANE infusion count for 1st line patients|
|avg_tax_inf_2Lplus| Average TAXANE infusion count for 2nd and above patients|
|ptnt_pct_use_tax_neoadjuvant| Percent of neoadjuvant patients using TAXANE|
|ptnt_pct_use_tax_adjuvant| Percent of adjuvant patients using TAXANE|
|ptnt_pct_use_tax_1L| Percent of 1st line patients using TAXANE|
|ptnt_pct_use_tax_2Lplus| Percent of 2nd and above line patients using TAXANE|
|ptnt_pct_surg_rmvl_neoadjuvant| Percent of neoadjuvant patients had removal surgery|
|ptnt_pct_surg_rmvl_adjuvant| Percent of adjuvant patients had removal surgery|
|ptnt_pct_surg_rmvl_1L| Percent of 1st line patients had removal surgery|
|ptnt_pct_surg_rmvl_2Lplus| Percent of 2nd and above line patients had removal surgery|
|ptnt_pct_surg_recons_neoadjuvant| Percent of neoadjuvant patients had reconstruction surgery|
|ptnt_pct_surg_recons_adjuvant| Percent of adjuvant patients had reconstruction surgery|
|ptnt_pct_surg_recons_1L| Percent of 1st line patients had reconstruction surgery|
|ptnt_pct_surg_recons_2Lplus| Percent of 2nd and above line patients had reconstruction surgery|
|ptnt_pct_use_hom_neoadjuvant| Percent of neoadjuvant patients using Hormone drugs|
|ptnt_pct_use_hom_adjuvant| Percent of adjuvant patients using Hormone drugs|
|ptnt_pct_use_hom_1L| Percent of 1st line patients using Hormone drugs|
|ptnt_pct_use_hom_2Lplus| Percent of 2nd and above patients using Hormone drugs|
|ptnt_pct_use_kad_1l_neoadjuvant| Percent of neoadjuvant patients using KADCYLA in 1st line|
|ptnt_pct_use_kad_1l_adjuvant| Percent of adjuvant patients using KADCYLA in 1st line|
|ptnt_pct_use_kad_1l_1L| Percent of 1st line patients using KADCYLA in 1st line|
|ptnt_pct_use_kad_1l_2Lplus| Percent of 2nd and above line patients using KADCYLA in 1st line|
|ptnt_pct_HER_neoadjuvant| Percent of neoadjuvant patients have Regimen HERCEPTIN mono|
|ptnt_pct_HER_adjuvant| Percent of adjuvant patients have Regimen HERCEPTIN mono|
|ptnt_pct_HER_1L| Percent of 1st line patients have Regimen HERCEPTIN mono|
|ptnt_pct_HER_2Lplus| Percent of 2nd and above line patients have Regimen HERCEPTIN mono|
|ptnt_pct_HER_PER_TAXANE_neoadjuvant| Percent of neoadjuvant patients have Regimen HER_PER_TAXANE|
|ptnt_pct_HER_PER_TAXANE_adjuvant| Percent of adjuvant patients have Regimen HER_PER_TAXANE|
|ptnt_pct_HER_PER_TAXANE_1L| Percent of 1st line patients have Regimen HER_PER_TAXANE|
|ptnt_pct_HER_PER_TAXANE_2Lplus| Percent of 2nd and above line patients have Regimen HER_PER_TAXANE|
|ptnt_pct_HER_TAXANE_neoadjuvant| Percent of neoadjuvant patients have Regimen HER_TAXANE|
|ptnt_pct_HER_TAXANE_adjuvant| Percent of adjuvant patients have Regimen HER_TAXANE|
|ptnt_pct_HER_TAXANE_1L| Percent of 1st line patients have Regimen HER_TAXANE|
|ptnt_pct_HER_TAXANE_2Lplus| Percent of 2nd and above line patients have Regimen HER_TAXANE|
|ptnt_pct_HER_plus_neoadjuvant| Percent of neoadjuvant patients have Regimen HER+Other|
|ptnt_pct_HER_plus_adjuvant| Percent of adjuvant patients have Regimen HER+Other|
|ptnt_pct_HER_plus_1L| Percent of 1st line patients have Regimen HER+Other|
|ptnt_pct_HER_plus_2Lplus| Percent of 2nd and above line patients have Regimen HER+Other|
|ptnt_pct_KAD_plus_neoadjuvant| Percent of neoadjuvant patients have Regimen KAD+Other|
|ptnt_pct_KAD_plus_adjuvant| Percent of adjuvant patients have Regimen KAD+Other|
|ptnt_pct_KAD_plus_1L| Percent of 1st line patients have Regimen KAD+Other|
|ptnt_pct_KAD_plus_2Lplus| Percent of 2nd and above line patients have Regimen KAD+Other|
|ptnt_pct_OTHER_neoadjuvant| Percent of neoadjuvant patients have Regimen OTHER|
|ptnt_pct_OTHER_adjuvant| Percent of adjuvant patients have Regimen OTHER|
|ptnt_pct_OTHER_1L| Percent of 1st line patients have Regimen OTHER|
|ptnt_pct_TCH_2Lplus| Percent of 2nd and above line patients have Regimen OTHER|
|ptnt_pct_TCH_neoadjuvant| Percent of neoadjuvant patients have Regimen TCH|
|ptnt_pct_TCH_adjuvant| Percent of adjuvant patients have Regimen TCH|
|ptnt_pct_TCH_1L| Percent of 1st line patients have Regimen TCH|
|ptnt_pct_TCH_2Lplus| Percent of 2nd and above line patients have Regimen TCH|
|Her2TestRate_Scaled| Her2 test rate|
|IHCTestRate_Scaled| IHC test rate|
|ISHTestRate_Scaled| ISH test rate|
|BRCATestRate_Scaled| BRCA test rate|
